Journal of Immunology Research / 2019 / Article / Tab 4

Research Article

Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients

Table 4

Comparative analysis of peripheral Th1, Treg, and DCs between healthy controls and CHB patients .

Healthy controlsTreatment-naïve patientsPatients with partial response to ETV

CD4+ T cell of PBMCs (%)60.30 (56.50–64.60)16.20 (7.30–56.40)49.30,△ (46.00–63.30)
Th1 of CD4+ T cells (%)60.40 (58.80–62.2)10.50 (8.70–14.1)10.00 (3.10–14.20)
Treg of CD4+ T cells (%)4.00 (3.09–5.18)12.68 (4.98–41.48)2.88△△ (0.50–8.32)
DCs of PBMCs (%)0.29 (0.27–0.40)0.07 (0.01–0.13)0.15,△△ (0.10–0.22)
PD-1 on Th1 (MFI)437.5 (412.8–452.8)523.1 (423.2–639.4)594.5,△△ (553.0–696.4)
PD-1 on Treg (MFI)1118.2 (856.8–2628.9)7164.1 (3022.4–25690.6)5677.8 (1372.3–11151.0)
PD-L1 on DCs (MFI)2010.30 (1683.5–2852.5)3432.1 (2080.6–6800.3)2530.3 (1764.3–4098.9)

Notes: , compared with healthy controls; , compared with healthy controls; , compared with treatment-naïve patients; △△, compared with treatment-naïve patients.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.